Annovis Bio, Inc.
NYSE:ANVSBiotechnology
+$0.00 today
- Market cap
- $51.64M
- Beta
- 1.24
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.47
Volume 1.35M
Average 1.08M
ANVS Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Annovis Bio, Inc.NYSE: ANVS
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$181.31M, compared with -$140.39M a year earlier.
Context
- Retained earnings amounted to 1116.2% of total assets at the end of Q1 FY2026, up 591.1 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -29.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (163.7M) USD
- Year-over-year change
- -21.4%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (163.7M) | -21.4% |
| FY2024 | 2024-12-31 | (134.85M) | -22.3% |
| FY2023 | 2023-12-31 | (110.26M) | -104.0% |
| FY2022 | 2022-12-31 | (54.05M) | -88.2% |
| FY2021 | 2021-12-31 | (28.73M) | — |
Retained Earnings vs competitors
How ANVS compares with its peers on the latest reported figures
- ANVS's Mar 2026 retained earnings of -$181.31M is the 2nd highest of the 6 companies compared; the peer median is -$309.23M.
- Its year-over-year change of -29.2% is the lowest of 6, against a peer median of -12.2%.
- Retained earnings amounts to 1116.2% of total assets for ANVS, versus a peer median of 923.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$116M | -26.4% | — | 328.4% | |
| Mar 2026 | -$181.31M | -29.2% | — | 1116.2% | |
| Mar 2026 | -$223.96M | -17.5% | — | 908.1% | |
| Mar 2026 | -$309.23M | -12.2% | — | 1613.9% | |
| Jun 2026 | -$387.33M | +2.8% | — | 964.5% | |
| Dec 2025 | -$991.48M | -10.2% | — | 923.8% | |
| Peer median (excluding ANVS) | -$309.23M | -12.2% | — | 923.8% | |
Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Annovis Bio, Inc.
NYSE:ANVS
Intrinsic Alpha fair value
Locked
Current Price
$1.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.